国家药监局：儿童用药和部分创新药、仿制药优先审评 State food and drug administration:Children's drugs and some innovative drugs/Generics priority review

　　据中国之声《全国新闻联播》报道，国家食品药品监督管理局今天表示，将深化药品审评审批制度改革，加快药品审评速度，并鼓励儿童药物研发。

According to the voice of China[The news broadcast]reports,The state food and drug administration said today,To deepen the reform of the drug approval for examination and approval system,To speed up the drug approval,And encourage children to drug development.

　　目前，我国大量低水平的药品研发和申报造成审评通道拥堵，而且随着创新药物申报的增加，由于审评资源和能力欠缺，更导致了药品审评时间过长，延误药品研发。

At present,Our country a large number of low levels of drug research and development and the application review channel jam,And with the increase of innovative drugs to declare,Due to the review of resources and lack of ability,More led to the drug approval time is too long,Delay in drug research and development.

　　国家食品药品监督管理局药品注册司司长王立丰表示，我国的药品多数为仿制药，审评策略也需调整，将优先审评临床亟需的仿制药。

The drug registration division of China's state food and drug administration Wang Lifeng said,Most drugs to generic drugs of our country,The review strategies also need to adjust,Will give priority to review the clinical needs of generic drugs.

　　王立丰：属于临床供应不足、市场竞争不充分、影响公众用药可及性和可负担性的药品，儿童用药、罕见病用药和特殊人群用药，以及经评估确认为临床急需的药品，实行优先审评。

Wang Lifeng:Belong to the clinical are in short supply/Market competition is not sufficient/Influence public drug accessibility and affordability of medicines,Medicine for children/Rare diseases preparation and special groups,And confirmed by the assessment for urgent clinical needs of drugs,A priority review.

　　此外，由于儿童用药的特殊性，儿童药物剂型一直紧缺，王立丰表示也将专门就儿童药物研发提出鼓励措施，并加大不良反应监测力度。(记者 李欣)

In addition,Due to the particularity of medicine for children,Children's medicines dosage form has been in short supply,Wang Lifeng said will also specialized drugs for children encourage measures are put forward,And increase the intensity of adverse reaction monitoring.(The reporter li xin)